Cargando…

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human

SIMPLE SUMMARY: The overall survival of ovarian cancer (OC) remains poor for most patients. Despite incorporation of novel therapeutic agents such as bevacizumab and PARP inhibitors to OC standard-of-care, efficacy is only observed in a subset of patients. Cancer vaccination has demonstrated effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Cheryl Lai-Lai, Rovelli, Raphaël, Sarivalasis, Apostolos, Kandalaft, Lana E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469371/ https://www.ncbi.nlm.nih.gov/pubmed/34572778 http://dx.doi.org/10.3390/cancers13184553

Ejemplares similares

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
por: Martin Lluesma, Silvia, et al.
Publicado: (2018)

Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015)

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2023)

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Cancer Vaccines in Ovarian Cancer: How Can We Improve?
por: Martin Lluesma, Silvia, et al.
Publicado: (2016)

Cell therapies in ovarian cancer
por: Sarivalasis, Apostolos, et al.
Publicado: (2021)

Paraneoplastic Cerebellar Ataxia Can Affect Prognosis in High-Grade Serous Ovarian Cancer: A Case Report
por: Liapi, Aikaterini, et al.
Publicado: (2020)

Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
por: Yakkala, Chakradhar, et al.
Publicado: (2019)

Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
por: Kandalaft, Lana E., et al.
Publicado: (2021)

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
por: Kandalaft, Lana E., et al.
Publicado: (2013)

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
por: Fritah, Hajer, et al.
Publicado: (2023)

Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
por: Liapi, Aikaterini, et al.
Publicado: (2023)

A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
por: Harari, Alexandre, et al.
Publicado: (2021)

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
por: Sarivalasis, Apostolos, et al.
Publicado: (2019)

Clinical translation section: accelerating the pace from bench to bedside
por: Kandalaft, Lana E, et al.
Publicado: (2011)

Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma
por: Yakkala, Chakradhar, et al.
Publicado: (2021)

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer
por: Matthaiou, Efthymia-Iliana, et al.
Publicado: (2022)

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2012)

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
por: Adams, Sarah F, et al.
Publicado: (2020)

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary
por: Malebranche, Mary, et al.
Publicado: (2020)

Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature
por: Wetterwald, Laureline, et al.
Publicado: (2023)

Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer
por: Lin, Chi-Kang, et al.
Publicado: (2016)

Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2011)

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018)

Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Ovarian cancer standard of care: are there real alternatives?
por: Pepa, Chiara Della, et al.
Publicado: (2015)

Harnessing preclinical models for the interrogation of ovarian cancer
por: Qin, Tianyu, et al.
Publicado: (2022)

Primary ovarian cancer chemotherapy: current standards of care
por: McGuire, W P, et al.
Publicado: (2003)

Advanced ovarian cancer: what should be the standard of care?
por: Goff, Barbara A.
Publicado: (2013)

Application of the CARE guideline as reporting standard in the Translational Cancer Research
Publicado: (2019)

Translational Research in Ovarian Cancer
por: Di Renzo, Maria Flavia, et al.
Publicado: (2020)

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
por: Graciotti, Michele, et al.
Publicado: (2017)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
por: Martinez, Alejandra, et al.
Publicado: (2020)

Mouse models of epithelial ovarian cancer for preclinical studies
por: Karakashev, Sergey, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7miu74aicggbkld4mqd1tboncs